How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion

• A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage. • Controlled studies may highlight a potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarzi-Puttini, Piercarlo, Marotto, Daniela, Antivalle, Marco, Salaffi, Fausto, Atzeni, Fabiola, Maconi, Giovanni, Monteleone, Giovanni, Rizzardini, Giuliano, Antinori, Spinello, Galli, Massimo, Ardizzone, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200131/
https://www.ncbi.nlm.nih.gov/pubmed/32376399
http://dx.doi.org/10.1016/j.autrev.2020.102574
Descripción
Sumario:• A correct patient risk stratification is of paramount importance for the proper management of economic and human resources. • Clinical trials are crucial to assessing immunosuppressant prophylaxis and treatment to avoid overuse and treatment shortage. • Controlled studies may highlight a potential preventive role of immunosuppressant in the development of Covid-19 severe forms; • Despite the risk of infection in rheumatic and gastroenterological diseases a conclusive link with COV-19 remains questionable.

Ejemplares similares